Type 2 Diabetes Treatment in China: Remission, Care & New Research
Type 2 diabetes is usually managed rather than described as “cured,” but some people can achieve remission. China offers standard endocrinology, obesity and metabolic care, complication treatment, metabolic surgery in selected patients, and active research into new drugs and procedures.
Short answer: travelling to China makes the most sense when there is a defined reason —
difficult control, obesity and metabolic disease, serious complications, metabolic-surgery evaluation, a specialist
second opinion or interest in a specific research protocol. For routine medication adjustment alone, long-haul
medical travel is often unnecessary.
✓ Remission, not cure hype
✓ Standard care separated from research
✓ Named-hospital review
✓ No obligation to book
Type 2 Diabetes: Treatment, Remission and the Word “Cure”
Type 2 diabetes can often be treated more effectively, and some people may reach remission under specific circumstances.
Remission is not the same as a guaranteed permanent cure. The useful question is which treatment goal applies to the
individual case: better glucose control, weight and metabolic treatment, complication care, metabolic-surgery evaluation,
or screening for a specific research study.
No page or provider can determine remission, treatment suitability or research eligibility without an individual clinical assessment.
Type 2 Diabetes Treatment in China: At a Glance
Medication, weight, kidney and cardiovascular risk, complications and hypoglycaemia risk still drive the treatment plan.
Remission is a defined medical outcome, not a promise of a permanent cure. Sustained weight loss can be an important route in selected patients.
China approved the glucokinase activator dorzagliatin in 2022. It is an approved medicine in China, not a stem-cell cure or a reason by itself to travel.
Current research includes remission-focused drug strategies, investigational procedures and cell-therapy studies. Access for foreign patients must be confirmed separately.
Evidence and registry information reviewed: 20 September 2026. Treatment/remission guidance layer updated: 24 September 2026.
Can Type 2 Diabetes Be Cured in China?
The more accurate medical term is remission. An international expert group convened by the ADA
proposed remission as HbA1c below 6.5% that persists for at least three months without usual glucose-lowering
pharmacotherapy. Remission does not mean diabetes can never return, so continued follow-up remains important.
China does not have a special universal “Type 2 diabetes cure” unavailable to the rest of medicine. What China does have is a large diabetes-care system, obesity and metabolic programmes, metabolic surgery, and active research into strategies aimed at improving glycemic control or achieving remission in selected patients.
Substantial and sustained weight loss
ADA 2026 notes that greater weight loss can have disease-modifying effects and may promote sustained Type 2 diabetes remission in some people.
A guaranteed permanent cure
Remission can relapse. A treatment advertisement promising permanent cure before reviewing disease duration, beta-cell function, weight and complications should be treated cautiously.
What Is Standard Type 2 Diabetes Treatment in China?
The foundation is not uniquely Chinese: treatment is individualized around glucose, weight, cardiovascular and kidney risk, complications and patient preferences. The current national framework is the CDS 中国糖尿病防治指南（2024版）: lifestyle measures, diabetes self-management education and support, and glucose-lowering treatment stratified by atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease, together with weight management. China may still be useful when a patient wants a tertiary specialist review or access to a specific programme.
| Treatment layer | What it can include | Why it matters for a medical traveller |
|---|---|---|
| Glucose-lowering medication | Metformin, GLP-1–based therapy, SGLT2 inhibitors, insulin and other agents according to the clinical situation. | A China trip should add specialist value, not merely duplicate a routine prescription that can be managed at home. |
| Weight management | Nutrition, activity, behavioral treatment and obesity pharmacotherapy when indicated. | Weight reduction can improve glucose control and, in some patients, contribute to remission. |
| Kidney / cardiovascular protection | Risk assessment and therapies selected for renal and cardiovascular benefit where appropriate. | Complex comorbidity can make a multidisciplinary tertiary hospital more relevant than a generic diabetes clinic. |
| Metabolic surgery | Gastric bypass, sleeve gastrectomy or another procedure in a carefully selected surgical candidate. | This is a major intervention requiring a high-volume multidisciplinary centre and long-term follow-up. |
| Clinical research | Investigational drugs, procedures or regenerative approaches under defined protocols. | Trial existence does not equal eligibility or foreign-patient access. |
What Is Actually Different About Type 2 Diabetes Treatment in China?
Most established Type 2 diabetes care in China follows the same evidence-based goals used internationally. The distinctive parts of the China landscape are selected domestic drug approvals, very large tertiary-hospital systems and an active research pipeline. Those differences should not be confused with a universal cure.
Dorzagliatin
Dorzagliatin is a dual-acting glucokinase activator approved in China in 2022 for Type 2 diabetes. It belongs to standard pharmacologic care in China, not to regenerative or stem-cell therapy.
Complex complications
A China hospital review can make more sense when diabetes is combined with difficult obesity, kidney disease, cardiovascular disease, diabetic foot disease or another problem requiring several specialties.
Do not confuse a study with an available treatment
A published case, a registry listing and a treatment an international patient can actually book are three different things. Current access must be checked with the exact hospital or study site.
Prepare a Type 2 case for review
Use this for difficult control, complications, metabolic care, or research. Remission is not a guaranteed cure.
Type 2 Research Eligibility and Foreign-Patient Access
There is no single eligibility checklist for all Type 2 diabetes studies. Each protocol uses its own age, HbA1c, disease-duration, medication, BMI, organ-function and follow-up rules. A registry status such as “Recruiting” does not automatically mean that a foreign patient can enroll.
| Question | What can be checked publicly | What still requires the study site |
|---|---|---|
| Diagnosis and stage | Type 2 diabetes, disease duration, HbA1c, medication history, BMI and protocol-specific risk criteria. | Whether the patient fits the study after full record review. |
| Current recruitment | Registry status and last update date. | Whether screening is actually open now and whether slots remain. |
| International patients | Public registries often do not answer this. | Nationality/residency rules, English communication, remote prescreening and required stay in China. |
| Costs | Some registries describe study treatment but not every patient expense. | Which medical costs are covered and which travel, lodging or non-protocol costs the patient pays. |
| Follow-up | Visit schedule may be listed in the protocol. | Whether part of follow-up can be completed outside China. |
Final eligibility and enrollment decisions belong to the investigator and participating hospital.
Weight Loss, Obesity Treatment and Type 2 Diabetes Remission
For many people with Type 2 diabetes and overweight or obesity, weight management is part of diabetes treatment itself.
ADA 2026 recommends treating weight as a primary goal alongside glycemia. Sustained weight loss above 10% often
produces larger metabolic benefits and can have disease-modifying effects, including possible remission.
Useful when the goal is durable weight loss
Not every patient needs medical travel for this. The value of China depends on whether a hospital offers a structured specialist programme that adds something unavailable locally.
Modern incretin-based treatment
Current standards prioritize medications with meaningful glucose and weight benefits when clinically appropriate. Drug choice still depends on the patient’s full medical profile.
Potential remission pathway in selected patients
ADA 2026 supports metabolic surgery as a weight and glycemic-management option for appropriate people with Type 2 diabetes and obesity, performed in experienced multidisciplinary centres.
Remission is not guaranteed. Surgery and large weight loss can produce major glycemic improvement,
but remission rates vary by procedure and patient characteristics, and diabetes can recur over time.
China Research Focused on Type 2 Diabetes Remission
China has studied remission-oriented strategies for years. The useful distinction is between remission research, experimental procedures, regenerative research and treatments that are already established clinical care.
NCT07374328 · TRED
Triple-regimen remission study in newly diagnosed Type 2 diabetes
This multicentre randomized study compares semaglutide-based and sitagliptin-based triple regimens in newly diagnosed Type 2 diabetes. Its primary outcome is diabetes remission rate at 11 months.
| Registry detail | Public record | Patient-facing interpretation |
|---|---|---|
| Population | Newly diagnosed Type 2 diabetes; protocol-defined age and HbA1c criteria. | This is not a general remission programme for everyone with established Type 2 diabetes. |
| Primary outcome | Diabetes remission rate. | The trial measures remission explicitly rather than using “cure” as a marketing label. |
| Registry status | Public record requires re-check | The public record previously listed Recruiting, but its estimated completion date has passed. Current screening must be confirmed before any travel plan. |
| International access | Not established by the public registry. | The study site must confirm whether overseas patients can be screened and whether the follow-up schedule is practical. |
Current Experimental Type 2 Diabetes Research in China
The current pipeline is broader than stem cells. Patients may encounter drug studies, investigational procedures and regenerative cell research. These should remain separate on the page because they have different evidence, risks and access rules.
Adipose-derived MSC Phase I
Beijing Tongren Hospital leads a Phase I study evaluating the safety, tolerability and preliminary efficacy of adipose-derived mesenchymal stem-cell injection in selected adults with Type 2 diabetes.
Current recruitment needs site confirmation
Pulse electric field ablation
Shanghai East Hospital has registered an investigational pulse-electric-field procedure for adults with Type 2 diabetes and suboptimal control on medication. It is a research procedure, not routine care.
Experimental procedure
HRS9531 tablet Phase II
A randomized placebo-controlled oral HRS9531 study is registered at Beijing Chaoyang Hospital and Qilu Hospital of Shandong University. The public record should be checked again before a patient inquiry.
Investigational medicine
Do not travel for a registry listing alone.
A public record may not tell you whether screening is currently open, whether foreigners are accepted,
how many return visits are required or which costs are covered.
Did China “Cure” Type 2 Diabetes With Stem Cells?
A published breakthrough is not the same as a routine cure.
A 2024 Cell Discovery report described a 59-year-old man with a 25-year history of Type 2 diabetes
who received autologous endoderm stem-cell-derived islet tissue after kidney transplantation. The result is an
important proof of concept, but it does not establish a treatment that every patient can book.
For the single experimental type 2 stem-cell-derived islet case reported in China, see the evidence review.
Stem-cell-derived islet tissue
The Chinese research case involved a highly selected patient and a defined research protocol. It should be described as experimental regenerative medicine, not as evidence of a universal permanent cure.
Beijing Tongren MSC Phase I
ChiCTR2600130840 is a different approach: adipose-derived mesenchymal stem cells, with safety and tolerability as the main Phase I focus. It should not be presented as the same treatment as the published islet-tissue case.
Why this matters: search results contain headlines using words such as “cure” and “reversal.”
Patients should ask for the exact cell product, protocol, hospital, eligibility criteria, follow-up and current
international-patient access before treating any offer as equivalent to the published research.
Stem-cell treatment is not routine Type 2 care. Recruiting studies are not an offer of treatment, and foreign enrollment is not confirmed. Use the clinical-trials guide before considering travel for a study.
Researching a stem-cell offer for Type 2 diabetes?
Our dedicated stem-cell guide separates published evidence, registered trials and commercial self-pay packages.
Who May Have a Real Reason to Consider Treatment in China?
A defined clinical problem
- Poor control despite a well-documented treatment plan
- Type 2 diabetes plus severe obesity or complex metabolic disease
- Metabolic-surgery evaluation
- Diabetic kidney, cardiovascular or foot complications requiring multidisciplinary care
- A specific registered China trial you want screened
- A named Chinese hospital has already requested your records
A problem that can likely be managed locally
- Routine metformin or other medication refill
- Standard HbA1c monitoring
- Generic diet advice
- Buying a common diabetes drug more cheaply
- A “permanent cure” advertisement with no named hospital or protocol
- Travelling before a hospital or trial confirms the case
When Diabetes Complications Change the Hospital Choice
In medical tourism, the “best diabetes hospital” often depends less on diabetes itself and more on the complication that needs to be managed.
Diabetic kidney disease
May require nephrology, renal imaging, medication review or dialysis-related planning in addition to endocrinology.
Heart and vascular risk
Complex coronary or vascular disease can make a multidisciplinary tertiary hospital more appropriate.
Ulcer / infection / ischemia
A diabetic-foot case may need vascular, infectious-disease, surgery and wound-care capability, not only endocrinology.
Retinopathy
Ophthalmic treatment can be a separate reason for hospital selection and may change the urgency of the trip.
How Much Does Type 2 Diabetes Treatment in China Cost?
There is no fixed Type 2 package price. A routine outpatient assessment and laboratory work-up are
completely different from inpatient treatment, diabetic-foot surgery, kidney care, metabolic surgery or experimental research.
Our dedicated cost guide uses official Chinese public-service price examples and separates hospital charges from international-patient travel, interpretation and accommodation costs. For an actual case, the useful number is a written estimate from the named hospital after records review.
Need a case-specific Type 2 treatment estimate?
Send the recent records and what you want evaluated. We can ask a suitable hospital for expected costs when the case can be reviewed.
What to Send for a Type 2 Diabetes Case Review
Core diabetes information
- Age, height, weight and BMI
- Year of diagnosis
- Latest HbA1c
- Current medication and doses
- Current insulin dose if used
- C-peptide if available
- Recent kidney and liver function
Complications and treatment goal
- Kidney disease / urine albumin results
- Cardiovascular history
- Eye / retinopathy reports
- Diabetic-foot history
- Previous bariatric / metabolic treatment
- Whether your goal is remission, surgery, complications or trial screening
- Any China hospital, trial or commercial offer you already found
What Happens After You Send Your Records
Review the records
We identify the main problem: routine control, obesity/metabolic disease, complications, surgery or research.
Identify the right type of care
A diabetes centre is not automatically the right destination if the main issue is kidney disease, diabetic foot or metabolic surgery.
Ask a named centre
We check whether a suitable hospital or research team can review the overseas case and what additional records are needed.
Get costs before travel
Hospital estimate, expected stay and travel planning come after the medical route is confirmed.
Have Type 2 Diabetes and Want to Know Whether China Offers a Useful Next Step?
Send your recent records and treatment goal. We’ll determine whether the case is best suited to standard endocrinology, metabolic treatment, complication care, surgery or a research inquiry before you plan travel.
✓ No cure guarantee
✓ Named-centre review
✓ Cost checked before travel
Related Diabetes Guides
Frequently Asked Questions
Short answers to the Type 2 diabetes questions international patients most often ask about China.
Can Type 2 diabetes be cured in China?
Type 2 diabetes is more accurately discussed in terms of remission rather than cure. International consensus defines remission as HbA1c below 6.5% for at least three months without usual glucose-lowering medication. Remission can occur in selected patients after major weight loss or other effective treatment, but it is not guaranteed and diabetes can recur.
What is the best treatment for Type 2 diabetes in China?
There is no single best treatment for every patient. The plan should reflect HbA1c, weight, kidney and cardiovascular disease, hypoglycemia risk, current medication, complications and personal treatment goals. For a medical traveller, the useful question is which Chinese centre fits the specific clinical problem.
Can weight loss put Type 2 diabetes into remission?
Yes, in some people. ADA 2026 notes that greater sustained weight loss can substantially improve glucose levels and may promote Type 2 diabetes remission. The probability varies with factors such as disease duration, beta-cell function, weight loss achieved and whether diabetes has already required insulin.
Is metabolic surgery used for Type 2 diabetes?
Yes, for selected surgical candidates with Type 2 diabetes and obesity. Current ADA guidance recognizes metabolic surgery as a weight and glycemic-management approach and recommends experienced, high-volume multidisciplinary centres. A Chinese hospital must still decide whether a specific international patient is an appropriate candidate.
Are there Type 2 diabetes clinical trials in China in 2026?
Yes. Current examples include remission-focused drug research, an investigational pulse-electric-field procedure in Shanghai and ChiCTR2600130840, a Phase I adipose-derived mesenchymal stem-cell study led by Beijing Tongren Hospital. Registry status does not establish that an international patient can enroll, so current screening and foreign-patient access must be confirmed with the study site.
How much does Type 2 diabetes treatment cost in China?
There is no fixed national package price. Cost depends on whether the patient needs a routine specialist review, medication and weight management, complication treatment, hospital admission, metabolic surgery or experimental research. The most useful estimate is a written quote from a named hospital after medical-record review.
What records should I send for a Type 2 diabetes review in China?
Send your age, height, weight, year of diagnosis, latest HbA1c, current medication and insulin dose if used, kidney and liver function, C-peptide if available, major cardiovascular, eye, kidney or foot complications, and whether your goal is remission, surgery, complication care or research screening.
Did China cure Type 2 diabetes with stem cells?
Chinese researchers have reported important regenerative-medicine results, including a published Type 2 diabetes case using stem-cell-derived islet tissue. That does not establish a routine permanent cure available to the general public. The published case, registered research studies and commercial stem-cell packages must be evaluated separately.
Evidence and Primary Sources
- American Diabetes Association — Standards of Care in Diabetes—2026. Current guidance on weight management, pharmacologic therapy, cardiovascular/kidney risk and metabolic surgery.
- International consensus on Type 2 diabetes remission. Remission is commonly defined as HbA1c below 6.5% for at least three months without usual glucose-lowering medication.
- Weng J. et al., The Lancet (2008), PMID 18502299. Chinese multicentre randomized research on short-term intensive insulin therapy, beta-cell function and glycaemic remission in newly diagnosed Type 2 diabetes.
- Nature — Advances in treatments for Type 2 diabetes: first China and then the world. Overview of China-specific Type 2 diabetes therapeutic innovation, including dorzagliatin, approved in China in 2022.
- Cell Discovery (2024) — personalized endoderm stem-cell-derived islet tissue. Pilot report describing a 59-year-old man with a 25-year history of Type 2 diabetes treated with autologous stem-cell-derived islet tissue.
- Chinese Clinical Trial Registry — ChiCTR2600130840. Phase I study evaluating safety, tolerability and preliminary efficacy of adipose-derived mesenchymal stem-cell injection in selected adults with Type 2 diabetes, led by Beijing Tongren Hospital.
- ClinicalTrials.gov — NCT07374328. Remission-focused randomized study in newly diagnosed Type 2 diabetes. Current screening status should be rechecked because the public record is time-sensitive.
- ClinicalTrials.gov — NCT07678866. Investigational pulse-electric-field ablation study in adults with Type 2 diabetes and suboptimal drug control at Shanghai East Hospital.
- ClinicalTrials.gov — NCT07599410. Phase II HRS9531 tablet study registered at Beijing Chaoyang Hospital and Qilu Hospital of Shandong University.
- ClinicalTrials.gov — NCT02302599. Completed randomized placebo-controlled Chinese UC-MSC research in adults with Type 2 diabetes; relevant as evidence, not as a current enrollment route.
Evidence note: a paper, registry listing or hospital publication does not automatically establish that an international self-pay patient can receive the same intervention. Current access must be confirmed with the exact site.
Medical note: This page is for medical-travel research and hospital matching. It is not medical advice and should not be used to stop or change diabetes medication without the treating clinical team.
Want Us to Check Which China Treatment Route Fits Your Case?
Send your records and treatment goal. We’ll separate routine care from remission-focused treatment, complications, surgery and experimental research, then identify the next realistic step before you travel.